Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 3 3Phase 1/2 2Phase 1 2Phase 4 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 14NIH 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1CNS 1

Conditions

Neuroblastoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Brain Neoplasms 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × plerixafor × Clear all
NCT01288573 2017-05-16

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

Sanofi

Phase 1/2 Completed
46 enrolled
CNS

Brain Neoplasms, Neuroblastoma

NCT00396968 2014-02-11

AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS

Sanofi

Phase 1/2 Withdrawn
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡